IONS — Ionis Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $12.32bn
- $11.31bn
- $705.14m
- 76
- 13
- 100
- 69
Annual income statement for Ionis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 729 | 810 | 587 | 788 | 705 |
| Cost of Revenue | |||||
| Gross Profit | 717 | 800 | 573 | 779 | 694 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 901 | 849 | 1,005 | 1,128 | 1,180 |
| Operating Profit | -172 | -38.8 | -418 | -340 | -475 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -135 | -29.1 | -258 | -334 | -460 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -480 | -28.6 | -270 | -366 | -454 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -444 | -28.6 | -270 | -366 | -454 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -444 | -28.6 | -270 | -366 | -454 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.04 | -0.053 | -2.96 | -2.53 | -3.04 |